HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Defend-Eeze Launches In US Zinc Cold Remedy Market

Executive Summary

Vespyr, incorporated in December 2021 after operating as Nurya when it acquired Cold-Eeze from Mylan in May that year, offers Defend-Eeze in lozenges containing echinacea, elderberry and vitamins C and D3 in addition to zinc.

You may also be interested in...



P&G Wraps Launch Of Super C Supplement Brand In Co-Packaging With DayQuil And NyQuil OTCs

P&G could be using a door left open in FDA’s 2015 proposed rule that questioned the safety of offering co-packaged supplements and drugs. With OTC drug and supplement firms always looking to drive sales growth, competitors large and small could follow P&G through the door.

Viatris Welcomes ‘Healthy Competition’ For UK OTC Erectile Dysfunction Top Spot

Viatris' marketing director Rob Elliott speaks to HBW Insight about how the company is investing in flagship OTC erectile dysfunction treatment Viagra Connect to ensure the brand keeps ahead of the growing competition. 

Sun Pharma US Business Co-packages OTC Emergency Contraceptive With Pregnancy Test

My After Plan has been available online and in stores since October 2020, shortly before Sun Pharma received registration for the trademark in the US. Recently, marketing and design consultants announced their work for Sun Pharma's Ohm Labs on My After Plan packaging.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel